Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine - Archive ouverte HAL Access content directly
Journal Articles The Journal of Allergy and Clinical Immunology: In Practice Year : 2021

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine

, , , (1) , , , , ,
1
Ian Pavord
  • Function : Author
Andrew Menzies-Gow
  • Function : Author
Roland Buhl
  • Function : Author
Mark Dransfield
  • Function : Author
Njira Lugogo
  • Function : Author
Oliver Keene
  • Function : Author
Eric Bradford
  • Function : Author
Steve Yancey
  • Function : Author

Dates and versions

hal-03654311 , version 1 (28-04-2022)

Identifiers

Cite

Ian Pavord, Andrew Menzies-Gow, Roland Buhl, Pascal Chanez, Mark Dransfield, et al.. Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. The Journal of Allergy and Clinical Immunology: In Practice, 2021, 9 (3), pp.1121-1132.e7. ⟨10.1016/j.jaip.2020.08.039⟩. ⟨hal-03654311⟩
4 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More